Establishment and validation of whole-cell based fluorescence assays to identify anti-mycobacterial compounds using the Acanthamoeba castellanii - Mycobacterium marinum host-pathogen system

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Kicka, Sébastien ^a   Trofimov, Valentin ^a   Harrison, Christopher ^b   Ouertatani Sakouhi, Hajer ^a   McKinney, John ^c   Scapozza, Leonardo ^a   Hilbi, Hubert ^b   Cosson, Pierre ^a   Soldati, Thierry ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ETHAMBUTOL; ETHIONAMIDE; FUSIDIC ACID; GREEN FLUORESCENT PROTEIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIORIDAZINE; TUBERCULOSTATIC AGENT;

ACANTHAMOEBA CASTELLANII; ANALYTICAL PARAMETERS; ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BIOLOGICAL MONITORING; CELL ASSAY; CONTROLLED STUDY; COST CONTROL; CYTOTOXICITY; DRUG DETERMINATION; FLUORESCENCE ANALYSIS; GROWTH INHIBITION; HOST PATHOGEN INTERACTION; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; VALIDATION STUDY; WHOLE CELL;

ACANTHAMOEBA CASTELLANII; ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE; HOST-PATHOGEN INTERACTIONS; MYCOBACTERIUM MARINUM;

EID: 84900401616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087834     Document Type: Article

References (89)

1. WHO-report (2011) http://www.who.int/tb/publications/global-report/2011/ en/index.html (accessed November 23, 2012).Global tuberculosis control.
2. Kumar V, Abbas AK, Fausto N, Mitchell R, Robbins N (2007) Basic pathology (8th edition): 516-522.
3. Armstrong JA, Hart PD (1971) Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 134: 713-740.
4. Bermudez LE, Goodman J (1996) Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 64: 1400-1406. (Pubitemid 26102407)
5. Warner DF, Mizrahi V (2007) The survival kit of Mycobacterium tuberculosis. Nat Med 13: 282-284. (Pubitemid 46376669)
6. Tailleux L, Neyrolles O, Honore-Bouakline S, Perret E, Sanchez F, et al. (2003) Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells. J Immunol 170: 1939-1948. (Pubitemid 36197413)
7. Russell DG (2001) Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2: 569-577.
8. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, et al. (2004) Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119: 753-766. (Pubitemid 40017683)
9. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, et al. (2010) Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140: 731-743.
10. Koul A, Herget T, Klebl B, Ullrich A (2004) Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol 2: 189-202. (Pubitemid 39490082)
11. Keane J, Remold HG, Kornfeld H (2000) Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 164: 2016-2020. (Pubitemid 30108758)
12. Behar SM, Divangahi M, Remold HG (2010) Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 8: 668-674.
13. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, et al. (1994) Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263: 678-681.
14. Fratti RA, Chua J, Vergne I, Deretic V (2003) Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci U S A 100: 5437-5442. (Pubitemid 36542723)
15. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, et al. (2005) Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 102: 4033-4038. (Pubitemid 40388550)
16. Neufert C, Pai RK, Noss EH, Berger M, Boom WH, et al. (2001) Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J Immunol 167: 1542-1549. (Pubitemid 32703154)
17. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, et al. (2004) Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304: 1800-1804. (Pubitemid 38787896)
18. Abdallah AM, Gey van Pittius NC, Champion PA, Cox J, Luirink J, et al. (2007) Type VII secretion-mycobacteria show the way. Nat Rev Microbiol 5: 883-891. (Pubitemid 47578389)
19. Gao LY, Guo S, McLaughlin B, Morisaki H, Engel JN, et al. (2004) A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion. Mol Microbiol 53: 1677-1693. (Pubitemid 39265314)
20. Cosma CL, Klein K, Kim R, Beery D, Ramakrishnan L (2006) Mycobacterium marinum Erp is a virulence determinant required for cell wall integrity and intracellular survival. Infect Immun 74: 3125-3133. (Pubitemid 43794501)
21. Davis JM, Clay H, Lewis JL, Ghori N, Herbomel P, et al. (2002) Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17: 693-702. (Pubitemid 35477789)
22. Davis JM, Ramakrishnan L (2009) The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136: 37-49.
23. Smith NH, Clifton-Hadley R (2008) Bovine TB: don't get rid of the cat because the mice have gone. Nature 456: 700.
24. Muller B, Borrell S, Rose G, Gagneux S (2013) The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 29: 160-169.
25. Arora P, Goyal A, Natarajan VT, Rajakumara E, Verma P, et al. (2009) Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis. Nat Chem Biol 5: 166-173.
26. Munoz-Elias EJ, Upton AM, Cherian J, McKinney JD (2006) Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60: 1109-1122.
27. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, et al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466.
28. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395. (Pubitemid 352775253)
29. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, et al. (2009) Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 53: 1290-1292.
30. Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, et al. (2008) A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 62: 1037-1045.
31. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. (Pubitemid 30435054)
32. Sonar VN, Crooks PA (2009) Synthesis and antitubercular activity of a series of hydrazone and nitrovinyl analogs derived from heterocyclic aldehydes. J Enzyme Inhib Med Chem 24: 117-124.
33. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, et al. (2009) Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53: 1314-1319.
34. Mitchison DA (2008) A new antituberculosis drug that selectively kills nonmultiplying Mycobacterium tuberculosis. Cell Host Microbe 3: 122-124.
35. Brown D (2007) Unfinished business: target-based drug discovery. Drug Discov Today 12: 1007-1012.
36. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40. (Pubitemid 46020284)
37. Goldman RC, Laughon BE (2009) Discovery and validation of new antitubercular compounds as potential drug leads and probes. Tuberculosis (Edinb) 89: 331-333.
38. Christophe T, Ewann F, Jeon HK, Cechetto J, Brodin P (2010) High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Future Med Chem 2: 1283-1293.
39. Sundaramurthy V, Barsacchi R, Samusik N, Marsico G, Gilleron J, et al. (2013) Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 13: 129-142.
40. Escaich S (2010) Novel agents to inhibit microbial virulence and pathogenicity. Expert Opin Ther Pat 20: 1401-1418.
41. Ferreras JA, Ryu JS, Di Lello F, Tan DS, Quadri LE (2005) Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol 1: 29-32.
42. Scherr N, Muller P, Perisa D, Combaluzier B, Jeno P, et al. (2009) Survival of pathogenic mycobacteria in macrophages is mediated through autophosphorylation of protein kinase G. J Bacteriol 191: 4546-4554.
43. Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, et al. (2010) Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog 6: e1000839.
44. Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, et al. (2007) Intracellular bacterial growth is controlled by a kinase network around PKB/ AKT1. Nature 450: 725-730. (Pubitemid 350207691)
45. Gluckman SJ (1995) Mycobacterium marinum. Clin Dermatol 13: 273-276.
46. Cosma CL, Sherman DR, Ramakrishnan L (2003) The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol 57: 641-676. (Pubitemid 37392957)
47. Hagedorn M, Soldati T (2007) Flotillin and RacH modulate the intracellular immunity of Dictyostelium to Mycobacterium marinum infection. Cell Microbiol 9: 2716-2733. (Pubitemid 47500521)
48. Welin A, Lerm M (2012) Inside or outside the phagosome? The controversy of the intracellular localization of Mycobacterium tuberculosis. Tuberculosis (Edinb) 92: 113-120.
49. Soldati T, Neyrolles O (2012) Mycobacteria and the intraphagosomal environment: take it with a pinch of salt(s)! Traffic 13: 1042-1052.
50. Salah IB, Ghigo E, Drancourt M (2009) Free-living amoebae, a training field for macrophage resistance of mycobacteria. Clin Microbiol Infect 15: 894-905.
51. Takaki K, Davis JM, Winglee K, Ramakrishnan L (2013) Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish. Nat Protoc 8: 1114-1124.
52. Cosson P, Soldati T (2008) Eat, kill or die: when amoeba meets bacteria. Curr Opin Microbiol 11: 271-276.
53. Hilbi H, Weber SS, Ragaz C, Nyfeler Y, Urwyler S (2007) Environmental predators as models for bacterial pathogenesis. Environ Microbiol 9: 563-575.
54. Steinert M, Heuner K (2005) Dictyostelium as host model for pathogenesis. Cell Microbiol 7: 307-314. (Pubitemid 40277911)
55. Greub G, Raoult D (2004) Microorganisms resistant to free-living amoebae. Clin Microbiol Rev 17: 413-433. (Pubitemid 38534035)
56. Adekambi T, Ben Salah S, Khlif M, Raoult D, Drancourt M (2006) Survival of environmental mycobacteria in Acanthamoeba polyphaga. Appl Environ Microbiol 72: 5974-5981. (Pubitemid 44414625)
57. Ben Salah I, Drancourt M (2010) Surviving within the amoebal exocyst: the Mycobacterium avium complex paradigm.
58. Steinert M, Birkness K, White E, Fields B, Quinn F (1998) Mycobacterium avium bacilli grow saprozoically in coculture with Acanthamoeba polyphaga and survive within cyst walls. Appl Environ Microbiol 64: 2256-2261. (Pubitemid 28252794)
59. Miltner EC, Bermudez LE (2000) Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. Antimicrob Agents Chemother 44: 1990-1994. (Pubitemid 30422963)
60. Kennedy GM, Morisaki JH, Champion PA (2012) Conserved mechanisms of Mycobacterium marinum pathogenesis within the environmental amoeba Acanthamoeba castellanii. Appl Environ Microbiol 78: 2049-2052.
61. Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, et al. (2013) A dual readout assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One 8: e60531.
62. Takaki K, Cosma CL, Troll MA, Ramakrishnan L (2012) An in vivo platform for rapid high-throughput antitubercular drug discovery. Cell Rep 2: 175-184.
63. Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, et al. (2012) A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. J Antimicrob Chemother 67: 1948-1960.
64. El-Etr SH, Subbian S, Cirillo SL, Cirillo JD (2004) Identification of two Mycobacterium marinum loci that affect interactions with macrophages. Infect Immun 72: 6902-6913. (Pubitemid 39552357)
65. Ramakrishnan L, Federspiel NA, Falkow S (2000) Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PEPGRS family. Science 288: 1436-1439. (Pubitemid 30366332)
66. Arafah S, Kicka S, Trofimov V, Hagedorn M, Andreu N, et al. (2013) Setting up and monitoring an infection of Dictyostelium discoideum with mycobacteria. Methods Mol Biol 983: 403-417.
67. Dionne MS, Ghori N, Schneider DS (2003) Drosophila melanogaster is a genetically tractable model host for Mycobacterium marinum. Infect Immun 71: 3540-3550. (Pubitemid 36637583)
68. Ramakrishnan L, Valdivia RH, McKerrow JH, Falkow S (1997) Mycobacterium marinum causes both long-term subclinical infection and acute disease in the leopard frog (Rana pipiens). Infect Immun 65: 767-773. (Pubitemid 27053249)
69. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, et al. (2012) Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog 8: e1002507.
70. Hilbi H, Hoffmann C, Harrison CF (2011) Legionella spp. outdoors: colonization, communication and persistence. Environ Microbiol Rep 3: 286-296.
71. Carvalho R, de Sonneville J, Stockhammer OW, Savage ND, Veneman WJ, et al. (2011) A high-throughput screen for tuberculosis progression. PLoS One 6: e16779.
72. Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ (2005) Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother 56: 104-109. (Pubitemid 41418342)
73. Varner TR, Bookstaver PB, Rudisill CN, Albrecht H (2011) Role of rifampin-based combination therapy for severe community-acquired Legionella pneumophila pneumonia. Ann Pharmacother 45: 967-976.
74. Lelong E, Marchetti A, Simon M, Burns JL, van Delden C, et al. (2011) Evolution of Pseudomonas aeruginosa virulence in infected patients revealed in a Dictyostelium discoideum host model. Clin Microbiol Infect 17: 1415-1420.
75. Froquet R, Lelong E, Marchetti A, Cosson P (2009) Dictyostelium discoideum: a model host to measure bacterial virulence. Nat Protoc 4: 25-30.
76. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73. (Pubitemid 29278954)
77. Pang KM, Lee E, Knecht DA (1998) Use of a fusion protein between GFP and an actin-binding domain to visualize transient filamentous-actin structures. Curr Biol 8: 405-408. (Pubitemid 28173999)
78. Blaschke TF, Skinner MH (1996) The clinical pharmacokinetics of rifabutin. Clin Infect Dis 22 Suppl 1: S15-21; discussion S21-12.
79. Hagedorn M, Rohde KH, Russell DG, Soldati T (2009) Infection by tubercular mycobacteria is spread by nonlytic ejection from their amoeba hosts. Science 323: 1729-1733.
80. Lee J, Remold HG, Ieong MH, Kornfeld H (2006) Macrophage apoptosis in response to high intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspase-independent pathway. J Immunol 176: 4267-4274. (Pubitemid 44264406)
81. Butler RE, Brodin P, Jang J, Jang MS, Robertson BD, et al. (2012) The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. PLoS One 7: e47573.
82. Golstein P, Aubry L, Levraud JP (2003) Cell-death alternative model organisms: why and which? Nat Rev Mol Cell Biol 4: 798-807. (Pubitemid 37229376)
83. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52: 790-795. (Pubitemid 37407806)
84. Oh CT, Moon C, Choi TH, Kim BS, Jang J (2013) Mycobacterium marinum infection in Drosophila melanogaster for antimycobacterial activity assessment. J Antimicrob Chemother 68: 601-609.
85. Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, et al. (2012) Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian J Med Res 136: 808-814.
86. Feuerriegel S, Koser CU, Richter E, Niemann S (2013) Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother 68: 1439-1440.
87. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416.
88. Kessler A, Schell U, Sahr T, Tiaden A, Harrison C, et al. (2013) The Legionella pneumophila orphan sensor kinase LqsT regulates competence and pathogen-host interactions as a component of the LAI-1 circuit. Environ Microbiol 15: 646-662.
89. Alibaud L, Rombouts Y, Trivelli X, Burguiere A, Cirillo SL, et al. (2011) A Mycobacterium marinum TesA mutant defective for major cell wall-associated lipids is highly attenuated in Dictyostelium discoideum and zebrafish embryos. Mol Microbiol 80: 919-934.